LungSign(TM) Study to Monitor Lung Cancer Recurrence
In this month of international Lung Cancer Awareness, Perceptronix Medical Inc. (Perceptronix) is pleased to announce the initiation of a new, longitudinal study with the Respiratory Department of Saint Paul’s Hospital (Vancouver, Canada). Dr. Pearce Wilcox, MD, FRCP and his team will evaluate the use of LungSign(TM) in monitoring for recurrence in subjects with recently re-sected lung cancer. Recurrence rate for lung cancer after resection can be in range from 5% to 15% thus early detection of recurrence among these patients could save many lives.
This entry was posted on Monday, November 10th, 2008 at 10:39 pm and is filed under Research, Early Detection. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.